Heart Failure Drugs Market- Global Forecasts to 2025
- April, 2019
- Domain: Healthcare - Pharmaceuticals
Pages:
88
Tables:
27
Charts:
41
Regions/Countries:
4 / 0
Companies:
10
Enquiry Hours:
11
- Get Free 10% Customization in this Report
[88 pages report] This market research report includes a detailed segmentation of the global heart failure drugs market by drug class (ACE inhibitors, beta blockers, diuretics, angiotensin receptor blockers, and others) and by region (North America, Europe, Asia Pacific, and Rest of the World).
Overview of the Global Heart Failure Drugs Market
Infoholic’s market research report predicts that the “Global Heart Failure Drugs Market” will grow at a CAGR of 9.1% during the forecast period. The market has witnessed good growth in the past few years and is sustaining due to increasing elderly population and increasing prevalence of cardiovascular diseases.
The growing market trend continues and is one of the progressively accepted markets in many countries worldwide. Heart failure drugs manufacturers are concentrating on procurement of funds and collaborating with universities to expand their R&D capabilities. Most of the revenue is generated from the leading players in the market with dominant sales from Novartis AG, GlaxoSmithKline PLC, AstraZeneca PLC, Bayer AG, and Pfizer Inc.
According to Infoholic Research analysis, North America leads the global heart failure drugs market in 2018 followed by Europe. The US dominates the market owing to the presence of a majority of the heart failure drugs manufacturers in the region. However, the fastest growth rate is anticipated to be in the APAC region due to the presence of large heart failure patient population and availability of wide range of drugs.
By Drug Class:
- ACE Inhibitors
- Angiotensin Receptor Blockers
- Beta Blockers
- Diuretics
- Others
The diuretics segment occupied the largest share in 2018. The existing guiding principle by the American College of Cardiology and the American Heart Association recommends that diuretics should be directed at doses adequate to attain optimum volume station and release cramming without making an extremely fast drop in intravascular capacity.
By Regions:
- North America
- Europe
- APAC
- RoW
North America is dominant in the global heart failure drugs market followed by Europe. The Duke University in North Carolina, US in collaboration with National Heart, Lung, Blood Institute (NHLBI) and Yale University is conducting phase III clinical trial “TRANSFORM-HF” a large-scale, pragmatic, randomized, unblinded clinical effectiveness study comparing torsemide versus furosemide as treatment for heart failure.
Heart Failure Drugs Market Research Competitive Analysis – The market is growing at a steady rate with a CAGR of 9.1% during the forecast period 2019–2025. Merger and acquisition, product launches, and strategic collaborations are some of the major strategies adopted by market leaders to maintain their leadership position in the market. For example, in February 2019, Amgen, Cytokinetics, and Servier initiated the METEORIC-HF, the second phase III clinical trial of omecamtiv mecarbil in patients with heart failure.
Universities and educational institutions are collaborating with the market players to develop effective drugs for the treatment of the heart failure. For instance, Yale University in collaboration with Boehringer Ingelheim is currently conducting a phase II clinical study; a minor pilot proof of concept study to not only prove the existence but also probe the mechanisms that are fundamental for the cardio-renal effects of empagliflozin in patients with heart failure.
Key Vendors:
- Novartis AG
- GlaxoSmithKline PLC
- AstraZeneca PLC
- Bayer AG
- Pfizer, Inc.
Key Competitive Facts
- Sclnow Biotechnology Co., Ltd. is studying to access the safety and efficiency of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating individuals suffering from heart failure. This treatment is in phase 1/2 currently.
- In January 2019, Sanofi and MyoKardia ended their heart disease drug collaboration.
Benefits – The report provides complete details about the sub-segments of the heart failure drugs market. Through this report, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives towards the disease management in the upcoming years along with details of the existing pureplay companies and new players entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.
Key Takeaways:
- Understanding the potential market opportunity with precise market size and forecast data.
- A detailed market analysis focusing on the growth of heart failure drugs
- Factors influencing the growth of the heart failure drugs
- In-depth competitive analysis of dominant and pureplay vendors.
- Prediction analysis of the heart failure drugs market in both developed and developing regions.
- Key insights related to major segments of the heart failure drugs
- Latest market trend analysis impacting the buying behavior of the consumers.
Key Stakeholders
1 Industry Outlook
1.1 Industry Overview
1.2 Total Addressable Market
1.2.1 Industry Trends
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market (SAM)
3.3 Industry Trends
3.4 Related Markets
3.4.1 Drug Eluting Stents
3.4.2 Active Pharmaceutical Ingredients (APIs)
3.4.3 Over the Counter Drugs (OTC)
4 Market Outlook
4.1 Market Segmentation
4.2 Porter 5 (Five) Forces
5 Market Characteristics
5.1 Guidelines Summary
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing elderly population
5.2.1.2 Increasing incidence of cardiovascular device across the globe
5.2.2 Restraints
5.2.2.1 Complex drug development process
5.2.2.2 Adverse effects of heart failure drugs
5.2.3 Opportunities
5.2.3.1 Market expansion opportunities in emerging nations
5.2.3.2 Novel heart failure medicines to fill the gap of unmet need in treatment
5.2.4 DRO – Impact Analysis
5.3 Key Stakeholders
6 Technology Types: Market Size and Analysis
6.1 Overview
6.2 Beta Blockers
6.3 ACE Inhibitors
6.4 Angiotensin Receptor Blockers (ARBs)
6.5 Diuretic
6.6 Others
7 Regions: Market Size and Analysis
7.1 Overview
7.2 North America
7.2.1 Overview
7.2.2 US
7.2.3 Canada
7.3 Europe
7.3.1 Overview
7.3.2 UK
7.3.3 Germany
7.4 Asia Pacific
7.4.1 Overview
7.4.2 India
7.4.3 China
7.4.4 Japan
7.5 Rest of the World
7.5.1 Overview
7.5.2 Africa
7.5.3 Brazil
8 Competitive Landscape
9 Vendors Profile
9.1 Novartis AG
9.1.1 Overview
9.1.2 Business Units
9.1.3 Geographic Presence
9.1.4 Business Focus
9.1.5 SWOT Analysis
9.1.6 Business Strategy
9.2 GlaxoSmithKline plc
9.2.1 Overview
9.2.2 Business Units
9.2.3 Geographic Presence
9.2.4 Business Focus
9.2.5 SWOT Analysis
9.2.6 Business Strategy
9.3 Bayer AG
9.3.1 Overview
9.3.2 Business Unit
9.3.3 Geographic Presence
9.3.4 Business Focus
9.3.5 SWOT Analysis
9.3.6 Business Strategy
9.4 Astra Zeneca PLC
9.4.1 Overview
9.4.2 Business Units
9.4.3 Geographic Presence
9.4.4 Business Focus
9.4.5 SWOT Analysis
9.4.6 Business Strategies
9.5 Pfizer, Inc.,
9.5.1 Overview
9.5.2 Business Units
9.5.3 Geographic Presence
9.5.4 Business Focus
9.5.5 SWOT Analysis
9.5.6 Business Strategies
10 Companies to Watch for
10.1 Merck & Co
10.1.1 Overview
10.2 Boehringer Ingelheim GmbH
10.2.1 Overview
10.3 Bristol-Myers Squibb
10.3.1 Overview
10.4 Mylan N.V.
10.4.1 Overview
10.5 Sanofi
10.5.1 Overview
10.6 Amgen Inc.
10.6.1 Overview
Annexure
Acronyms
TABLE 1 TOP ACQUISITIONS IN CARDIOVASCULAR INDUSTRY 10
TABLE 2 HEART FAILURE DRUGS MARKET REVENUE, BY PRODUCT TYPE, 2018–2025 ($MILLION) 30
TABLE 3 PROJECTIONS – CVD TOTAL COSTS THROUGH 2035 41
TABLE 4 PRESCRIPTIONS USED IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
IN UK 43
TABLE 5 NUMBER OF PEOPLE WITH THE FOUR HEART CONDITIONS IN BRAZIL, 2015 48
TABLE 6 NOVARTIS AG: OFFERINGS 52
TABLE 7 NOVARTIS AG: RECENT DEVELOPMENTS 53
TABLE 8 GLAXOSMITHKLINE PLC: OFFERINGS 59
TABLE 9 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 60
TABLE 10 BAYER AG: OFFERINGS 64
TABLE 11 BAYER AG: RECENT DEVELOPMENTS 64
TABLE 12 ASTRAZENECA PLC: OFFERINGS 69
TABLE 13 ASTRAZENECA PLC: RECENT DEVELOPMENTS 70
TABLE 14 PFIZER, INC.: OFFERINGS 75
TABLE 15 PFIZER, INC.: RECENT DEVELOPMENTS 76
TABLE 16 MERCK & CO: SNAPSHOT 81
TABLE 17 MERCK & CO: RECENT DEVELOPMENTS 81
TABLE 18 BOEHRINGER INGELHEIM GMBH: SNAPSHOT 82
TABLE 19 BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS 82
TABLE 20 BRISTOL-MYERS SQUIBB: OVERVIEW 83
TABLE 21 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENTS 83
TABLE 22 MYLAN N.V.: OVERVIEW 84
TABLE 23 MYLAN N.V.: RECENT DEVELOPMENTS 85
TABLE 24 SANOFI: SNAPSHOT 85
TABLE 25 SANOFI: RECENT DEVELOPMENTS 86
TABLE 26 AMGEN INC.: OVERVIEW 86
TABLE 27 AMGEN INC.: RECENT DEVELOPMENTS 87
Research Framework
Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:
- Data Collation (Primary & Secondary)
- In-house Estimation (Based on proprietary data bases and Models)
- Market Triangulation
- Forecasting
Market related information is congregated from both primary and secondary sources.
Primary sources
Involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources
Include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.
